Clinical Trial: Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs)
Study Status: Completed
Recruit Status: Completed
Condition:
Immune Checkpoint Inhibitor
Endocrine Toxicity
Study Type: Observational
Official Title: Endocrine-related Adverse Events Caused by Immune Checkpoint Inhibitors
Brief Summary:
Immune checkpoint inhibitor (ICI) includes agents that block cytotoxic T-cell-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1). Since the FDA-approval of the CTLA-4 inhibitor ipilimumab in 2011, ICI drugs have emerged as a powerful new tool in the treatment for several advanced cancers. Now indications for ICI have expanded dramatically due to their efficacy and include a wide array of cancer types. However, the administration of ICI,…
Read more